Halozyme Therapeutics announced a $1 billion share repurchase program, planning to buy back at least $400 million in 2026, reflecting strong cash flow and confidence in its business. The company reported a 42% year-over-year revenue increase to $377 million in Q1 2026, driven by royalty growth and product sales. Halozyme reiterated its 2026 financial guidance, expecting total revenue between $1.71 billion and $1.81 billion, with royalty revenue growth of 30-35% and adjusted EBITDA growth of 71-83%. Recent collaborations with major pharma firms and new product approvals support a robust outlook for sustained royalty income into the 2030s and beyond.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
